Literature DB >> 22416898

Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS.

Rahma Warsame1, Ingrid E Kohut, Angela Dispenzieri.   

Abstract

POEMS syndrome is a rare paraneoplastic condition related to myeloma. Because it is rare, there is very little known about treatment options. The use of potentially neurotoxic chemotherapeutic drugs is of concern in a disease whose major manifestation is neuropathy. Herein, we describe an extraordinary response to the combination of cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in a patient with relapsed, life-threatening POEMS syndrome.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22416898     DOI: 10.1111/j.1600-0609.2012.01780.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

Review 1.  How I treat POEMS syndrome.

Authors:  Angela Dispenzieri
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

2.  Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation.

Authors:  Yoshimi Ishii; Etsuko Yamazaki; Yasufumi Ishiyama; Eri Yamamoto; Yukako Hattori; Maki Hagihara; Naoto Tomita; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2013-10-29       Impact factor: 2.490

Review 3.  POEMS Syndrome: an Enigma.

Authors:  Rahma Warsame; Uday Yanamandra; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2017-04       Impact factor: 4.213

4.  Characteristics of 1946 Cases of POEMS Syndrome in Chinese Subjects: A Literature-Based Study.

Authors:  Yong Wang; Li-Bo Huang; Yi-Hua Shi; Huan Fu; Zhen Xu; Guo-Qing Zheng; Yan Wang
Journal:  Front Immunol       Date:  2019-06-21       Impact factor: 7.561

Review 5.  POEMS SYNDROME: an Update.

Authors:  Andrea Nozza
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-09-01       Impact factor: 2.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.